Aldosterone and thrombosis formation: Implications for ischemic and atherosclerotic heart disease

Journal of Endocrinological Investigation

Volumn 29, Issue 7, 2006, Pages 675-676

  Calo L A ^a   Armanini, D ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; CANRENONE; EPLERENONE; GLYCYRRHETINIC ACID; MATRIX METALLOPROTEINASE; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR; PROTEIN P22; SPIRONOLACTONE; TRANSFORMING GROWTH FACTOR BETA;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; DRUG RECEPTOR BINDING; ENDOCRINE FUNCTION; FIBRINOLYSIS; HUMAN; HYPERALDOSTERONISM; ISCHEMIC HEART DISEASE; LETTER; NONHUMAN; OXIDATION REDUCTION POTENTIAL; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PERIPHERAL BLOOD MONONUCLEAR CELL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK BENEFIT ANALYSIS; THROMBOGENESIS; THROMBOSIS;

EID: 33749022234     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03344170     Document Type: Letter

References (13)

1. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341: 709-17.
2. Pitt B, Remme W, Zannad F, et al. Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348: 1309-21.
3. Wehling M. Rapid effects of aldosterone: relevant in cardiac ischemia? Hypertension 2005, 46: 27-8.
4. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45: 1243-8.
5. Bodary PF, Sambaziotis C, Wickenheiser KJ, Rajagopalan S, Pitt B, Eitzman DT. Aldosterone promotes thrombosis formation after arterial injury in mice. Arterioscler Thromb Vasc Biol 2006, 26: 233.
6. Calò LA, Zaghetto F, Pagnin E, et al. Effect of aldosterone and glycyrrhetinic acid on the protein expression of PAI-1 and p22(phox) in human mononuclear leukocytes. J Clin Endocrinol Metab 2004, 89: 1973-6.
7. Huber K, Christ G, Wojta J, Gulba D. Plasminogen activator inhibitor Type-1 in cardiovascular disease. Status Report 2001. Thromb Res 2001, 103: S7-19.
8. Sun Y, Zhang J, Zhang JQ, Ramirez FJ. Local angiotensin II and transforming growth factor beta 1 in renal fibrosis of rats. Hypertension 2000, 35: 1078-84.
9. Weber KT. From inflammation to fibrosis: a stiff strech of highway. Hypertension 2004, 43: 716-9.
10. Armanini D, Strasser T, Weber PC. Characterization of aldosterone binding sites in circulating human mononuclear leukocytes. Am J Physiol 1985, 248: E388-90.
11. Armanini D, Fiore C, Calò LA. Mononuclear leucocyte mineralocorticoid receptors: a possible link between aldosterone and atherosclerosis. Hypertension 2006, 47: e4-e5.
12. Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, Miyazaki M. Eplerenone inhibits atherosclerosis in nohuman primates. Hypertension 2005, 46: 1135-9.
13. Keidar S, Hayek T, Kaplan M, et al. Effect of eplerenone, a selective aldosterone blocker, on blood pressure, serum and macrophage oxidative stress, and arteriosclerosis in apolipoprotein E-deficent mice. J Cardiovasc Pharmacol 2003, 41: 955-63.